A Phase 3 interventional study of Levonorgestrel IUS (Mirena, BAY86-5028) and Medroxyprogesterone acetate in Menorrhagia, sponsored by Bayer. Completed at 54 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-09.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Menorrhagia by Bayer — none open to participants now, none under way, none of them phase 3. Menorrhagia · Bayer.
Among the 19 studies in Menorrhagia by Bayer, this one is one of 2 that started in 2006, is one of 6 in phase 3, and was the 2nd registered.
206 studies on the registry are indexed under Menorrhagia; 35 are open to participants now.
Browse Menorrhagia studies →None of the 19 studies in Menorrhagia by Bayer is open now. The open studies under Menorrhagia, anywhere →
Of the 23 Menorrhagia studies recruiting now, 4 (17%) set no upper age limit and 19 (83%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 95 across 149 interventional studies indexed under Menorrhagia.
Median enrollment 153 across the 9 interventional studies, 886 across the 10 observational. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Menorrhagia by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the levonorgestrel-releasing intrauterine system is effective in decreasing menstrual blood loss.
Acronyms in the Adverse Event Section:
This study has previously been posted by Berlex, Inc. and Schering AG, Germany. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc., Schering AG Germany has been renamed to Bayer HealthCare AG, Germany.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
Drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
Drug: Medroxyprogesterone acetate
Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6)
The MBL for each cycle included intermenstrual bleeding in addition to withdrawal bleeding. Baseline MBL was the composite MBL measured during each of the cycles during the Screening Phase. End-of-study MBL was measured during Cycle 6 of the Treatment Phase.
Time frame: Baseline and up to 6 months
Percentage of Patients With Successful Treatment
End-of-study MBL \< 80 mL and a decrease to a value no greater than 50% of the Baseline MBL was considered to be treatment success.
Time frame: At 6 months
Percent Change From Baseline MBL to End of Study MBL (Cycle 6)
The percent change = {(End of Study MBL - Baseline MBL)/Baseline MBL} x 100.
Time frame: Baseline and up to 6 months
Absolute Change From Baseline MBL to Mid-study MBL (Cycle 3)
The MBL for each cycle included intermenstrual bleeding in addition to withdrawal bleeding. Mid-study MBL was measured during Cycle 3 of the Treatment Phase.
Time frame: Baseline and up to 3 months
Percent Change From Baseline MBL to Mid-study MBL (Cycle 3)
The percent change = {(Mid-study MBL - Baseline MBL)/Baseline MBL} x 100.
Time frame: Baseline and up to 3 months
Percentage of Subjects Who Completed the Study in Levonorgestrel Intrauterine System (LNG IUS) Group
Time frame: Baseline and up to 6 months
Total Number of Bleeding Days
In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts.
Time frame: Baseline and up to 6 months
Total Number of Spotting and Bleeding Days
In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts.
Time frame: Baseline and up to 6 months
Total Number of Spotting Days
In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts.
Time frame: Baseline and up to 6 months
Total Number of Bleeding Episodes
A bleeding episode is defined as a light, normal or heavy bleeding, during a minimum of one day. In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts.
Time frame: Baseline and up to 6 months
Percent Change in Hemoglobin
Time frame: Baseline and up to 6 months
Percent Change in Hematocrit
Time frame: Baseline and up to 6 months
Percent Change in Serum Ferritin
Time frame: Baseline and up to 6 months
Percentage of Patients With Improvement in the Investigator Global Assessment Scale
"Improved" is classified as 'very much improved', 'much improved', or 'improved' and "not improved" is classified as 'no change', 'worse', 'much worse', or 'very much worse'
Time frame: Up to 6 months
Percentage of Patients With Improvement in the Patients Overall Assessment Scale
"Improved" is classified as 'very much improved', 'much improved', or 'improved' and "not improved" is classified as 'no change', 'worse', 'much worse', or 'very much worse'.
Time frame: Up to 6 months
| Milestone | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Started | 82 | 83 |
| Completed | 73 | 72 |
| Not completed | 9 | 11 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Protocol violation | 0 | 4 |
| Withdrew: Withdrawal by subject | 1 | 3 |
The MBL for each cycle included intermenstrual bleeding in addition to withdrawal bleeding. Baseline MBL was the composite MBL measured during each of the cycles during the Screening Phase. End-of-study MBL was measured during Cycle 6 of the Treatment Phase.
| milliliter (mL) | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6) | -128.78 (-393.6 to 1242.2) | -17.7 (-271.5 to 78.6) |
End-of-study MBL \< 80 mL and a decrease to a value no greater than 50% of the Baseline MBL was considered to be treatment success.
| Percentage of participants | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Percentage of Patients With Successful Treatment | 84.8 | 22.2 |
The percent change = {(End of Study MBL - Baseline MBL)/Baseline MBL} x 100.
| Percent change | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Percent Change From Baseline MBL to End of Study MBL (Cycle 6) | -70.75 ± 88.31 | -21.54 ± 35.79 |
The MBL for each cycle included intermenstrual bleeding in addition to withdrawal bleeding. Mid-study MBL was measured during Cycle 3 of the Treatment Phase.
| milliliter (mL) | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Absolute Change From Baseline MBL to Mid-study MBL (Cycle 3) | -115.13 (-405.8 to 54.4) | -3.15 (-270.9 to 146.7) |
The percent change = {(Mid-study MBL - Baseline MBL)/Baseline MBL} x 100.
| Percent change | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Percent Change From Baseline MBL to Mid-study MBL (Cycle 3) | -61.71 ± 41.76 | -11.11 ± 42.46 |
| percentage of participants | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours |
|---|---|
| 0 days | 97.53 |
| 30 days | 95.06 |
| 60 days | 93.83 |
| 90 days | 92.59 |
| 120 days | 91.36 |
| 150 days | 90.12 |
| 180 days | 90.12 |
In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts.
| days | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Baseline | 5.64 ± 1.573 | 5.64 ± 1.280 |
| Cycle 1 | 10.23 ± 5.784 | 5.17 ± 1.349 |
| Cycle 2 | 7.88 ± 5.256 | 5.15 ± 1.459 |
| Cycle 3 | 5.92 ± 4.505 | 5.25 ± 1.648 |
| Cycle 4 | 4.77 ± 4.455 | 4.82 ± 1.591 |
| Cycle 5 | 3.77 ± 4.560 | 4.89 ± 1.325 |
| Cycle 6 | 4.16 ± 4.631 | 5.29 ± 1.835 |
In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts.
| days | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Baseline | 6.30 ± 1.744 | 6.80 ± 1.990 |
| Cycle 1 | 19.70 ± 7.894 | 6.65 ± 2.265 |
| Cycle 2 | 17.46 ± 7.293 | 7.46 ± 2.294 |
| Cycle 3 | 11.89 ± 7.415 | 6.92 ± 2.569 |
| Cycle 4 | 10.42 ± 6.426 | 6.66 ± 2.372 |
| Cycle 5 | 10.25 ± 7.359 | 6.89 ± 2.482 |
| Cycle 6 | 8.58 ± 7.024 | 6.90 ± 2.834 |
In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts.
| days | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Baseline | 1.23 ± 1.191 | 1.84 ± 1.638 |
| Cycle 1 | 9.47 ± 6.933 | 1.48 ± 1.613 |
| Cycle 2 | 9.58 ± 7.073 | 2.31 ± 2.004 |
| Cycle 3 | 7.27 ± 6.421 | 2.27 ± 2.150 |
| Cycle 4 | 5.65 ± 5.079 | 1.84 ± 1.767 |
| Cycle 5 | 6.48 ± 5.869 | 2.00 ± 2.297 |
| Cycle 6 | 5.38 ± 6.330 | 2.23 ± 2.532 |
A bleeding episode is defined as a light, normal or heavy bleeding, during a minimum of one day. In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts.
| number of bleeding episodes | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Baseline | 1.01 ± 0.075 | 1.03 ± 0.115 |
| Cycle 1 | 1.75 ± 0.707 | 0.98 ± 0.222 |
| Cycle 2 | 0.88 ± 0.653 | 1.01 ± 0.194 |
| Cycle 3 | 0.99 ± 0.647 | 0.97 ± 0.228 |
| Cycle 4 | 0.76 ± 0.615 | 0.99 ± 0.202 |
| Cycle 5 | 0.77 ± 0.755 | 1.01 ± 0.208 |
| Cycle 6 | 0.70 ± 0.739 | 1.04 ± 0.359 |
| percent change | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Baseline to cycle 3 | 3.82 (-7.1 to 25.3) | 1.65 (-15.4 to 20.2) |
| Cycle 3 to cycle 6 | 3.28 (-7.9 to 18.0) | 0.83 (-11.0 to 16.9) |
| Baseline to cycle 6 | 7.50 (-3.6 to 44.0) | 1.87 (-17.9 to 33.3) |
| percent change | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Baseline to cycle 3 | 4.9 (-8 to 21) | 0.0 (-15 to 21) |
| Cycle 3 to cycle 6 | 2.4 (-11 to 13) | 0.0 (-14 to 18) |
| Baseline to cycle 6 | 5.4 (-7 to 26) | 0.0 (-21 to 26) |
| percent change | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Baseline to cycle 3 | 13.8 (-67 to 300) | 0.0 (-78 to 380) |
| Cycle 3 to cycle 6 | 48.3 (-51 to 293) | 16.7 (-78 to 560) |
| Baseline to cycle 6 | 68.8 (-52 to 1440) | 14.3 (-87 to 540) |
"Improved" is classified as 'very much improved', 'much improved', or 'improved' and "not improved" is classified as 'no change', 'worse', 'much worse', or 'very much worse'
| percentage | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Cycle 3 | 94.7 | 71.2 |
| Cycle 6 | 93.6 | 61.0 |
"Improved" is classified as 'very much improved', 'much improved', or 'improved' and "not improved" is classified as 'no change', 'worse', 'much worse', or 'very much worse'.
| percentage | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| Cycle 3 | 93.3 | 74.0 |
| Cycle 6 | 93.6 | 67.1 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | — | 1/82 (1.2%) | 67/82 (81.7%) |
| Medroxyprogesterone Acetate (MPA) | — | 0/83 (0%) | 52/83 (62.7%) |
| Event | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| EndometriosisReproductive system and breast disorders | 1/82 | 0/83 |
| Event | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) |
|---|---|---|
| HeadacheNervous system disorders | 13/82 | 9/83 |
| Ovarian cystReproductive system and breast disorders | 10/82 | 2/83 |
| Vaginitis bacterialInfections and infestations | 9/82 | 3/83 |
| Urinary tract infectionInfections and infestations | 6/82 | 3/83 |
| Weight increasedInvestigations | 5/82 | 6/83 |
| SinusitisInfections and infestations | 5/82 | 4/83 |
| Upper respiratory tract infectionInfections and infestations | 5/82 | 1/83 |
| AcneSkin and subcutaneous tissue disorders | 5/82 | 5/83 |
| HypertensionVascular disorders | 5/82 | 1/83 |
| Abdominal pain lowerGastrointestinal disorders | 3/82 | 5/83 |
| Age Continuous(years) | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) | Total |
|---|---|---|---|
| Mean | 38.3 (26 to 50) | 39.3 (26 to 53) | 38.8 (26 to 53) |
| Sex: Female, Male(Participants) | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) | Total |
|---|---|---|---|
| Female | 82 | 83 | 165 |
| Male | 0 | 0 | 0 |
| Body mass index(kg/m²) | Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours | Medroxyprogesterone Acetate (MPA) | Total |
|---|---|---|---|
| Mean | 27.19 ± 3.903 | 27.36 ± 4.610 | 27.28 ± 4.263 |
The record gives a start of Jul 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levonorgestrel